Tasquinimod, an oral quinolone-3-carboxamide with anti-tumor activity in preclinical models of prostate cancer, has been tested in patients with minimally symptomatic castration-resistant prostate cancer (CRPC), showing promising inhibitory effects on the occurrence of metastasis and delayed disease progression. Although its mode of action is not fully understood, tasquinimod presumably exerts its unique anti-tumor action through inhibition of angiogenesis and immunomodulation. In clinical studies, tasquinimod demonstrated anti-tumor activity in prostate cancer in combination with a mild-to-moderate side effect profile. With single-agent tasquinimod, dose-limiting toxicity was amylase elevation without signs of pancreatitis and sinus tachyc...
Apalutamide (ARN-509) is a second-generation androgen receptor (AR) antagonist that was developed to...
CONTEXT: Until recently, the only approved agent for metastatic castration-resistant prostate cancer...
Prostate cancer is the second deadliest cancer in the US and the fourth most common cancer among Sau...
Background:Tasquinimod is a quinoline-3-carboxamide derivative with anti-angiogenic activity. Two op...
Stuart Charles Williamson, Alice Elizabeth Hartley, Rakesh HeerNorthern Institute for Cancer Researc...
Treatment options have significantly expanded in recent years for men with metastatic castration-res...
BACKGROUND Tasquinimod (ABR-215050) is an orally active quinoline-3-carboxamide analog that has comp...
Purpose Tasquinimod, a novel oral therapy targeting the tumor microenvironment, significantly improv...
IF 11.855International audienceBackgroundThis phase II study was conducted to assess clinical effica...
Background: Previous work has demonstrated immunomodulatory, anti-tumor, anti-metastatic and anti-an...
Background: Tasquinimod is a small molecule with immunomodulatory, anti-angiogenic, and anti-met...
This review examines the development and efficacy of novel treatment options for advanced prostate c...
Castrate-resistant prostate cancer (CRPC) occurs when disease progresses in the presence of castrate...
BACKGROUND:Niclosamide, an FDA-approved anti-helminthic drug, has activity in preclinical models of ...
Nonmetastatic castration-resistant prostate cancer (nmCRPC) - defined as prostate-specific antigen (...
Apalutamide (ARN-509) is a second-generation androgen receptor (AR) antagonist that was developed to...
CONTEXT: Until recently, the only approved agent for metastatic castration-resistant prostate cancer...
Prostate cancer is the second deadliest cancer in the US and the fourth most common cancer among Sau...
Background:Tasquinimod is a quinoline-3-carboxamide derivative with anti-angiogenic activity. Two op...
Stuart Charles Williamson, Alice Elizabeth Hartley, Rakesh HeerNorthern Institute for Cancer Researc...
Treatment options have significantly expanded in recent years for men with metastatic castration-res...
BACKGROUND Tasquinimod (ABR-215050) is an orally active quinoline-3-carboxamide analog that has comp...
Purpose Tasquinimod, a novel oral therapy targeting the tumor microenvironment, significantly improv...
IF 11.855International audienceBackgroundThis phase II study was conducted to assess clinical effica...
Background: Previous work has demonstrated immunomodulatory, anti-tumor, anti-metastatic and anti-an...
Background: Tasquinimod is a small molecule with immunomodulatory, anti-angiogenic, and anti-met...
This review examines the development and efficacy of novel treatment options for advanced prostate c...
Castrate-resistant prostate cancer (CRPC) occurs when disease progresses in the presence of castrate...
BACKGROUND:Niclosamide, an FDA-approved anti-helminthic drug, has activity in preclinical models of ...
Nonmetastatic castration-resistant prostate cancer (nmCRPC) - defined as prostate-specific antigen (...
Apalutamide (ARN-509) is a second-generation androgen receptor (AR) antagonist that was developed to...
CONTEXT: Until recently, the only approved agent for metastatic castration-resistant prostate cancer...
Prostate cancer is the second deadliest cancer in the US and the fourth most common cancer among Sau...